Related Experiment Video

Updated: Jul 11, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

1.0K

Therapeutic Approaches Targeting Ferroptosis in Cardiomyopathy

Yanqian Ruan1, Ling Zhang2, Lina Zhang1

  • 1School of Public Health, Zhejiang Provincial Key Laboratory of Pathophysiology, Health Science Center of Ningbo University, Ningbo, 315211, Zhejiang, People's Republic of China.

Cardiovascular Drugs and Therapy
|November 6, 2023
PubMed

Insights

Cardiomyopathy, a heart condition, is linked to ferroptosis, a cell death process. Therapies targeting ferroptosis show promise in treating and preventing heart failure associated with this cell death mechanism.

Area of Science:

  • Cardiovascular Medicine
  • Cellular Biology
  • Pharmacology

Background:

  • Cardiomyopathy encompasses heart diseases leading to severe heart failure.
  • Ferroptosis, a distinct form of programmed cell death, is implicated in cardiomyopathy pathogenesis.
  • Existing research suggests therapeutic interventions targeting ferroptosis can mitigate cardiomyopathy progression.

Purpose of the Study:

  • To review current understanding of ferroptosis mechanisms.
  • To elucidate the role of ferroptosis in the development of cardiomyopathy.
  • To explore therapeutic strategies for ferroptosis-associated cardiomyopathy.

Main Methods:

  • Literature review of recent scientific discoveries.
  • Analysis of studies on ferroptosis regulation by small molecules and herbal medicine.
  • Synthesis of information on ferroptosis's role in heart disease.

Main Results:

  • Ferroptosis is a key factor in the development of cardiomyopathy.
  • Small molecule drugs and herbal medicine components can modulate ferroptosis.
  • Modulating ferroptosis offers a potential therapeutic avenue for cardiomyopathy.

Conclusions:

  • Ferroptosis plays a significant role in cardiomyopathy.
  • Targeting ferroptosis presents a promising strategy for preventing and treating cardiomyopathy.
  • Further research into ferroptosis mechanisms can advance cardiovascular disease therapies.

Keywords:
CardiomyopathyFerroptosisHerbal medicineTherapeutic approaches

More Related Videos

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts09:21

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

943
Author Spotlight: Advantages of Pressure-Volume Loop Measurement Method in Cardiovascular Research04:27

Author Spotlight: Advantages of Pressure-Volume Loop Measurement Method in Cardiovascular Research

Published on: January 12, 2024

533

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Necrosis01:16

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
15